glimepiride has been researched along with Fractures, Bone in 2 studies
glimepiride: structure given in first source
Fractures, Bone: Breaks in bones.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect of empagliflozin on bone fractures and bone mineral density in patients with type 2 diabetes in pooled placebo-controlled trial data and a head-to-head study versus glimepiride." | 4.98 | Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. ( Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C, 2018) |
| "Patients with type 2 diabetes have an increased risk of fragility fractures; the cause is unclear but is likely multifactorial." | 2.82 | COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES. ( Baeres, FM; Garber, A; Gilbert, MP; Holst, JJ; Marre, M; Pratley, RE; Thomsen, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kohler, S | 1 |
| Kaspers, S | 1 |
| Salsali, A | 1 |
| Zeller, C | 1 |
| Woerle, HJ | 1 |
| Gilbert, MP | 1 |
| Marre, M | 1 |
| Holst, JJ | 1 |
| Garber, A | 1 |
| Baeres, FM | 1 |
| Thomsen, H | 1 |
| Pratley, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes[NCT00294723] | Phase 3 | 746 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in body weight from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.8 | -2.70 |
| Lira 1.2 | -1.89 |
| Glimepiride | 0.95 |
Change in body weight from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.8 | -2.43 |
| Lira 1.2 | -1.68 |
| Glimepiride | 1.05 |
Change in body weight from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.8 | -2.45 |
| Lira 1.2 | -2.05 |
| Glimepiride | 1.12 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -15.82 |
| Lira 1.2 | -9.36 |
| Glimepiride | 1.97 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -12.06 |
| Lira 1.2 | -5.45 |
| Glimepiride | 4.57 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -25.57 |
| Lira 1.2 | -15.21 |
| Glimepiride | -5.29 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 104 weeks (end of 52-week extension) (NCT00294723)
Timeframe: week 0, week 104
| Intervention | percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.8 | -0.88 |
| Lira 1.2 | -0.59 |
| Glimepiride | -0.28 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 156 weeks (NCT00294723)
Timeframe: week 0, week 156
| Intervention | percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.8 | -0.71 |
| Lira 1.2 | -0.44 |
| Glimepiride | -0.16 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 52 weeks (end of double-blind period) (NCT00294723)
Timeframe: week 0, week 52
| Intervention | percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.8 | -1.14 |
| Lira 1.2 | -0.84 |
| Glimepiride | -0.51 |
Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -37.15 |
| Lira 1.2 | -27.34 |
| Glimepiride | -24.85 |
Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 156 weeks. The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 156
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -34.83 |
| Lira 1.2 | -25.68 |
| Glimepiride | -23.84 |
Change in mean postprandial glucose (PPG) based on self-measured 8-point plasma glucose profiles from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measurements of plasma glucose were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. (NCT00294723)
Timeframe: week 0, week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -37.4 |
| Lira 1.2 | -30.8 |
| Glimepiride | -24.5 |
Change in mean prandial increments of plasma glucose from baseline (week 0) to 104 weeks (end of 52-week extension). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 104
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -11.76 |
| Lira 1.2 | -8.28 |
| Glimepiride | -7.95 |
Change in mean prandial increments (incr.) of plasma glucose from baseline (week 0) to 156 weeks. The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 156
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -11.01 |
| Lira 1.2 | -7.53 |
| Glimepiride | -7.97 |
Change in mean prandial increments of plasma glucose from baseline (week 0) to 52 weeks (end of double-blind period). The 8 time points for self-measured 8-point plasma glucose profiles were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner), at bedtime, and at 3:00 AM ± 30 min. Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between post- and pre-meal values (for breakfast, lunch and dinner) divided by three. (NCT00294723)
Timeframe: week 0, week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Lira 1.8 | -9.6 |
| Lira 1.2 | -8.4 |
| Glimepiride | -5.6 |
Total number of hypoglycaemic episodes occuring from baseline (week 0) to 104 weeks (end of the 52-week extension). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 0-104
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Glimepiride | 0 | 533 | 405 |
| Lira 1.2 | 0 | 68 | 133 |
| Lira 1.8 | 1 | 71 | 87 |
Total number of hypoglycaemic episodes occuring from week 104 to end of trial (week 195). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL. (NCT00294723)
Timeframe: weeks 104-195
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Glimepiride | 1 | 34 | 4 |
| Lira 1.2 | 0 | 3 | 1 |
| Lira 1.8 | 0 | 13 | 3 |
1 review available for glimepiride and Fractures, Bone
| Article | Year |
|---|---|
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials, | 2018 |
1 trial available for glimepiride and Fractures, Bone
| Article | Year |
|---|---|
COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
Topics: Adult; Aged; Bone Density; Calcium; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fracture | 2016 |